DEFA14A: Aurinia Pharmaceuticals Responds to Lucien Selce's Proposals, Recommends Shareholders Vote for Incumbent Directors

Aurinia Pharmaceuticals addresses concerns regarding Lucien Selce's proposals, highlighting his background and lack of transparency, while reaffirming the company's strategic direction and recommending shareholders vote for the current board.

Summary

• Aurinia Pharmaceuticals has issued a letter to shareholders addressing concerns raised by Lucien Selce regarding the company's direction.
• The company highlights Selce's background, including past charges of money laundering and insider trading, raising doubts about his integrity and motives.
• Aurinia criticizes Selce's proposals as lacking substance and concrete details, and questions his request for control of the company without providing specific plans or board nominees.
• The company emphasizes its strong business momentum, including year-over-year revenue growth and progress towards cash flow positivity.
• Aurinia also highlights the recommendation from Glass Lewis, a leading independent proxy advisor, to vote for the re-election of all nine incumbent directors.
• The company reiterates its focus on commercial execution, maximizing free cash flows, and advancing its autoimmune pipeline.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While it defends the company's position against shareholder concerns and highlights positive financial results, it also acknowledges risks and uncertainties. The recommendation from Glass Lewis is a positive signal.

Positives

• Aurinia has a strong cash position with over $320 million in cash, cash equivalents, restricted cash, and investments.
• The company is advancing its autoimmune pipeline with AUR200 in Phase 1 clinical trials.
• Aurinia achieved approximately 46% year-over-year growth in total net revenue and 40% in net product revenue in Q1 2024.
• The company is ahead of projections to be cash flow positive in Q2 2024, excluding share repurchases.
• Glass Lewis recommends shareholders vote for the current board, supporting the company's direction.

Negatives

• Lucien Selce's proposals are criticized as lacking substance and concrete details.
• Selce's background, including past charges of money laundering and insider trading, raises concerns about his integrity.
• ISS's recent recommendations against three of Aurinia's directors relate to the company's 2023 say-on-pay proposal.

Risks

• The company's actual future financial and operational results may differ from its expectations.
• Difficulties may arise in completing the commercialization of voclosporin.
• The market for the LN business may not be as estimated.
• Aurinia may face unanticipated expenses.
• The company may not be able to obtain sufficient supply to meet commercial demand for voclosporin in a timely fashion.
• Results from clinical studies and third-party reports may not be accurate.
• Third-party service providers may not comply with their obligations.
• Aurinia's assets or business activities may be subject to disputes that may result in litigation or other legal claims.

Future Outlook

Aurinia expects to be cash flow positive, excluding share repurchases, in the second quarter of 2024 and is focused on delivering transformative therapies.

Management Comments

• Aurinia's Board of Directors and management team have been taking a range of actions to position the Company for sustainable success and build value for shareholders.
• We believe Aurinia Pharmaceuticals is well positioned for future growth from its FDA-approved drug, voclosporin (brand name LUPKYNIS).

Industry Context

Aurinia is operating in the biopharmaceutical industry, focused on autoimmune diseases. The company's response to shareholder concerns and emphasis on corporate governance are relevant in the context of increasing shareholder activism.

Comparison to Industry Standards

• Aurinia's focus on commercial execution and pipeline development aligns with industry best practices for biopharmaceutical companies.
• The company's cash position and progress towards profitability are positive indicators compared to other companies in the sector.
• The recommendation from Glass Lewis supports the company's governance and strategic direction, which is a positive signal for investors.

Stakeholder Impact

• Shareholders are being asked to vote on the re-election of directors.
• The company's performance and strategic direction will impact shareholders, employees, and patients.
• The company's focus on delivering therapies to treat targeted patient populations with high unmet medical needs will impact patients.

Next Steps

• Shareholders will vote on the re-election of directors at the upcoming Annual General Meeting (AGM).
• The company will continue to focus on commercial execution, maximizing free cash flows, and advancing its autoimmune pipeline.

Key Dates

Keywords

Aurinia Pharmaceuticals, Lucien Selce, Proxy Statement, Board of Directors, LUPKYNIS, Voclosporin, Autoimmune Diseases, Cash Flow Positive, Shareholder Value, Corporate Governance